Alligator Bioscience: European Commission grants orphan drug designation to Alligator Bioscience's HLX22 to treat gastric cancer
Alligator Bioscience, a clinical─stage biotechnology company, announces that the European Commission has granted orphan drug designation (ODD) to HLX22, an anti─HER2 monoclonal antibody, for the treatment
Read full article »
Alligator is a Sweden-based biotechnology firm that develops and commercializes antibody-based immunotherapies for the treatment of cancer.
Read more